1 Volume 2018; Issue 01 Obstetrics and Gynecology: Open Access Review Article Kohzadi M, et al. Gynecol Obstet Open Acc: OBOA-122. New Findings on Anti-Mullerian Hormone in Polycystic Ovarian Syndrome Patients Mozhgan Kohzadi, Farzaneh Choobsaz, Mozafar Khazaei * Department of Fertility and Infertility Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran * Corresponding author: Mozafar Khazaei, Department of Fertility and Infertility Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. Tel: +988334274617-21; Fax: +988334281563; Email: mkhazaei1345@yahoo.com Citation: Kohzadi M, Choobsaz F, Khazaei M (2018) New Findings on Anti Mullerian Hormone in Polycystic Ovarian Syn- drome Patients. Gynecol Obstet Open Acc: OBOA-122. DOI: 10.29011/ OBOA-122. 100022 Received Date: 02 February, 2018; Accepted Date: 20 March, 2018; Published Date: 28 March, 2018 DOI: 10.29011/ OBOA-122. 100022 Abstract Polycystic Ovarian Syndrome (PCOS) is the most complex and common endocrine disorders in women, associated with a wide range of symptoms such as, irregular menstrual cycle, acne, hirsutism and weight gain. Despite extensive re- search, the pathogenesis of the disease is not known yet. Genetic, endocrine and environmental factors have been discussed in the pathogenesis of PCOS. Compared with the general population, PCOS patients are at a greater risk of uterine cancer, cardiovascular problems and metabolic complications. Each of these issues may lead to death. However; Anti-Mullerian Hormone (AMH) is a unique biomarker of ovarian function in assessment of women’s health. In addition, this can be used in treatment of infertility. It is argued that the amount of AMH in women with PCOS is more than normal but the cause of this increase has not been identifed yet. Therefore, more research is needed to understand the role of this hormone in the pathophysiology of PCOS and its relationship with other factors. In this study fndings regarding the anti-Mullerian hormone and polycystic ovary syndrome are reviewed. Keywords: Anti-Mullerian Hormone; Infertility; Metabolic disorders; Polycystic ovary syndrome Introduction Polycystic Ovary Syndrome (PCOS) also known as chronic hyper androgenic syndrome or indolence ovary is associated with anovulation, and is said to be the most common endocrine, metabolic and multifactorial disorders, in women of childbearing age. This syndrome may have possible genetic origin and has the prevalence about 4-18%. According to the Stein and Leventhal in 1935, this syndrome known with menstrual problems, protests clinical and biochemical hyperandrogenism and polycystic ovaries [1]. PCOS have mentioned as 75% of infertility due to anovulation. In addition to infertility, this syndrome is associated with insulin resistance, hyperinsulinemia, hyperandrogenism, metabolic syndrome and increased risk of diabetes properties [2-4]. Although, the pathogenesis of PCOS is complex and not fully understood, but studies suggest that androgens and insulin are major causes of the disease [5]. Insulin has a major effect on the ovarian follicles, so hyperinsulinemia is associated with stunted growth of premature ovarian follicles [6]. Hyperandrogenism can increase the number of follicles in women with PCOS [7]. People with PCOS have higher levels of testosterone, insulin, triglycerides and cholesterol as well as lower levels of Sexual Hormone Binding Globulin (SHBG), and Follicle Stimulating Hormone (FSH) compared to healthy individuals [7, 8] (Figure 1).